FDA Approves Aurlumyn (iloprost) as the First Medication to Treat Severe Frostbite
The U.S. Food and Drug Administration (FDA) approved Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation. The FDA granted the approval of Aurlumyn to Eicos Sciences Inc.
Frostbite can occur in several stages, ranging from mild frostbite that does not require medical intervention and does not cause permanent skin damage, to severe frostbite when both the skin and underlying tissue are frozen and blood flow is stopped, sometimes requiring amputation. Iloprost, the active ingredient in Aurlumyn, is a vasodilator (a drug that opens blood vessels) and prevents blood from clotting.
